Breo Ellipta inhalers contains a combination of fluticasone and vilanterol. Inflammatory substances in the body are prevented from being released by fluticasone. By relaxing muscles in the airways, Vilanterol works as a bronchodilator to improve breathing. By reducing inflammation (swelling) and opening up the airways in your lungs, fluticasone (corticosteroid) and vilanterol (long-acting beta-agonist) make breathing easier.

It is possible to use Breo Ellipta alone or in combination with other medications. However, it would be vital to discuss any medication usage with your healthcare specialist.

The drug Breo Ellipta is classified as a Beta2 agonist, corticosteroids, inhalants, and respiratory inhalant combinations.

The Breo Ellipta combination is a once-daily medicine used in adults with asthma and COPD (chronic obstructive pulmonary disease) to treat symptoms and prevent attacks of bronchospasm and asthma.

Breo Ellipta is intended for long-term treatment of COPD. For people with asthma, this medicine is used for short-term treatment until symptoms are controlled by other medications.

In people with asthma, Vilanterol alone may increase their risk of death. As a combination product, fluticasone and vilanterol do not increase this risk.

The safety and effectiveness of Breo Ellipta in children are unknown. Breo is only available as a brand-name drug. Currently, it isn’t available in generic form.

Ellipta is also found in Trelegy.